New resource available view now
POTOMAC, MARYLAND / November 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease,
POTOMAC, MARYLAND – November 13, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging Artificial Intelligence (“AI”) to develop innovative
POTOMAC, MARYLAND November 10, 2025 / IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today announced
POTOMAC, MARYLAND – November 03, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for
POTOMAC, MARYLAND – October 22, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today
POTOMAC, MARYLAND – October 14, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for
POTOMAC, MARYLAND October 10, 2025 / IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today announced
IGC-1C Targets Tau Protein’s Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed POTOMAC, MARYLAND – October 7, 2025 – IGC Pharma, Inc. (“IGC
POTOMAC, MD, September 29, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced the addition of a new clinical trial site to its ongoing Phase 2 study evaluating IGC-AD1, an
POTOMAC, MARYLAND, September 24, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced preclinical findings on TGR-63, the Company’s investigational small-molecule candidate for Alzheimer’s disease. The data demonstrate that TGR-63